Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-04 4:32 pm Purchase |
2025-03-28 | 13G | Sutro Biopharma, Inc. STRO |
RA Capital Management, L.P. | 4,434,637 5.300% |
4,434,637 (New Position) |
Filing History |
| 2025-03-31 4:57 pm Purchase |
2025-03-27 | 13D | Acumen Pharmaceuticals, Inc. ABOS |
RA Capital Management, L.P. | 15,016,063 24.800% |
34,445 (+0.23%) |
Filing History |
| 2025-03-31 4:54 pm Purchase |
2025-03-27 | 13D | Tyra Biosciences, Inc. TYRA |
RA Capital Management, L.P. | 10,684,890 20.100% |
7,750 (+0.07%) |
Filing History |
| 2025-03-17 7:58 pm Purchase |
2025-03-13 | 13D | Mineralys Therapeutics, Inc. MLYS |
RA Capital Management, L.P. | 6,287,597 9.900% |
1,338,290 (+27.04%) |
Filing History |
| 2025-03-10 4:33 pm Purchase |
2025-03-06 | 13D | Janux Therapeutics, Inc. JANX |
RA Capital Management, L.P. | 11,971,377 19.900% |
1,528,196 (+14.63%) |
Filing History |
| 2025-03-03 8:17 pm Unchanged |
2025-02-27 | 13D | 89bio, Inc. ETNB |
RA Capital Management, L.P. | 20,013,733 13.700% |
0 (Unchanged) |
Filing History |
| 2025-02-21 4:15 pm Purchase |
2025-02-19 | 13D | Solid Biosciences Inc. SLDB |
RA Capital Management, L.P. | 7,989,820 9.900% |
3,631,342 (+83.32%) |
Filing History |
| 2025-02-18 4:25 pm Purchase |
2025-02-10 | 13D | Sionna Therapeutics, Inc. SION |
RA Capital Management, L.P. | 10,445,322 23.700% |
10,445,322 (New Position) |
Filing History |
| 2025-02-14 6:43 pm Sale |
2024-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 7,777,942 8.900% |
-682,148 (-8.06%) |
Filing History |
| 2025-02-14 6:43 pm Purchase |
2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 11,520,120 9.900% |
1,047,745 (+10.00%) |
Filing History |
| 2025-02-14 6:42 pm Sale |
2024-12-31 | 13G | Tenaya Therapeutics, Inc. TNYA |
RA Capital Management, L.P. | 0 0.000% |
-7,980,736 (Position Closed) |
Filing History |
| 2025-02-14 6:42 pm Purchase |
2024-12-31 | 13G | NewAmsterdam Pharma Company N.V. NAMS |
RA Capital Management, L.P. | 10,875,454 9.900% |
1,779,865 (+19.57%) |
Filing History |
| 2025-02-14 6:41 pm Sale |
2024-12-31 | 13G | Recursion Pharmaceuticals, Inc. RXRX |
RA Capital Management, L.P. | 7,725,096 2.000% |
-7,659,519 (-49.79%) |
Filing History |
| 2025-02-14 6:40 pm Purchase |
2024-12-31 | 13G | Protara Therapeutics, Inc. TARA |
RA Capital Management, L.P. | 3,431,713 9.900% |
1,358,638 (+65.54%) |
Filing History |
| 2025-02-14 6:39 pm Sale |
2024-12-31 | 13G | MacroGenics, Inc. MGNX |
RA Capital Management, L.P. | 0 0.000% |
-4,053,077 (Position Closed) |
Filing History |
| 2025-02-14 6:39 pm Sale |
2024-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
RA Capital Management, L.P. | 0 0.000% |
-3,073,119 (Position Closed) |
Filing History |
| 2025-02-14 6:38 pm Sale |
2024-12-31 | 13G | GlycoMimetics, Inc. GLYC |
RA Capital Management, L.P. | 0 0.000% |
-6,383,000 (Position Closed) |
Filing History |
| 2025-02-14 6:37 pm Purchase |
2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
RA Capital Management, L.P. | 3,181,818 4.700% |
86,682 (+2.80%) |
Filing History |
| 2025-02-14 6:36 pm Sale |
2024-12-31 | 13G | Evolent Health, Inc. EVH |
RA Capital Management, L.P. | 3,577,197 3.100% |
-4,701,906 (-56.79%) |
Filing History |
| 2025-02-14 6:34 pm Sale |
2024-12-31 | 13G | Ensysce Biosciences, Inc. ENSC |
RA Capital Management, L.P. | 0 0.000% |
-98,400 (Position Closed) |
Filing History |